At the Synta Pharmaceuticals Corp. (the "Company") 2012 annual meeting of stockholders held on June 14, 2012, at which a quorum was present, the stockholders of the Company voted on and approved the following matters, which are described in detail in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 27, 2012: (1) to elect Keith R. Gollust and Robert N. Wilson as Class II directors to each serve for a three-year term expiring at the Company's annual meeting of stockholders in 2015, and until their successors have been elected and qualified, or until their earlier death, resignation, retirement or removal ("Proposal 1"); and (2) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012 ("Proposal 2").

A plurality of the votes cast were voted for the elections of Mr. Gollust and Mr. Wilson as directors, and the proposal to ratify the appointment of Ernst & Young LLP was approved by a majority of the shares voting affirmatively or negatively. The tabulation of votes with respect to the proposals was as follows:

Proposal 1 - Election of Directors:



                      For       Withheld   Broker Non-Votes
Keith R. Gollust   33,934,241    266,530         13,783,568
Robert N. Wilson   33,866,799    333,972         13,783,568

Proposal 2 - Ratification of Independent Registered Public Accounting Firm:

For Against Abstain
47,940,310 28,201 15,828